Arjo ABFRA:A39 +1.64%73 Days Payable is 31.36 as of Mar. 2026, which is 18% below its 10-year median of 38.20. GuruFocus rates FRA:A39 with a GF Score™ of 73/100 and a GF Value™ of €3.27 (Significantly Undervalued). The stock has 5 warning signs investors should review. Among 115 Medical Distribution companies, Arjo AB ranks worse than 89.57% on this metric.
Arjo AB's average Accounts Payable for the
three
months ended in Mar. 2026 was €49.4 Mil. Arjo AB's Cost of Goods Sold for the
three
months ended in Mar. 2026 was €143.8 Mil.
Hence, Arjo AB's Days Payable for the
three
months ended in Mar. 2026 was 31.36.
The historical rank and industry rank for Arjo AB's Days Payable or its related term are showing as below:
FRA:A39'
s Days Payable Range Over the Past 10 Years
Min: 31.62 Med: 38.2 Max: 54.84
Current: 31.62
During the past 13 years, Arjo AB's highest Days Payable was 54.84. The lowest was 31.62. And the median was 38.20.
FRA:A39's Days Payable is ranked worse than 89.57% of 115
companies
in the Medical Distribution industry
Industry Median: 79.81
vs FRA:A39: 31.62
Arjo AB's Days Payable
declined
from Mar. 2025 (32.70) to Mar. 2026 (31.36).
It may suggest that Arjo ABaccelerated paying its suppliers.
Arjo AB Days Payable Related Terms
Arjo AB Days Payable Historical Data
* Premium members only.
The historical data trend for Arjo AB's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, Arjo AB's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Arjo AB Days Payable vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Arjo AB's Days Payable distribution charts can be found below:
* The bar in red indicates where Arjo AB's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Arjo AB's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Arjo AB (FRA:A39) has a Days Payable of 31.36 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Arjo AB and its competitors. This is 18% below median its historical median of 38.20. Over the past decade, Arjo AB's Days Payable has ranged from 31.62 to 54.84. According to the industry distribution chart, Arjo AB ranks #103 out of 115 companies in the Medical Distribution industry, placing it in the top 89.6%.
Is Arjo AB's Days Payable too high?
Arjo AB's current Days Payable of 31.36 is 18% below median its 10-year median of 38.20. Over the past 10 years, this metric has ranged from a low of 31.62 to a high of 54.84. The Medical Distribution industry median Days Payable is 79.81. Arjo AB's value of 31.36 is 60.7% below this industry median. Based on the distribution chart, Arjo AB ranks #103 out of 115 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, Arjo AB has a GF Score™ of 73/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Arjo AB's Days Payable compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Arjo AB ranks #103 out of 115 companies for Days Payable. This places Arjo AB in the lower half of its industry. The industry median Days Payable is 79.81. Arjo AB's value of 31.36 is 60.7% below this benchmark. Historically, Arjo AB's own Days Payable has ranged from 31.62 to 54.84 over the past decade. While the company's 10-year median is 38.20 vs. the industry median of 79.81, Arjo AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Distribution company?
The median Days Payable among Medical Distribution companies is 79.81, based on 115 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Arjo AB's current Days Payable of 31.36 is 60.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Arjo AB and its competitors. For the Medical Distribution industry, the median Days Payable is 79.81 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Arjo AB's current Days Payable is 31.36, which is 18% below median its own 10-year median of 38.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arjo AB stock overvalued right now?
Based on GuruFocus' analysis, Arjo AB (FRA:A39) is currently considered Significantly Undervalued. The stock's GF Value™ is €3.27, compared to a current price of €2.23 — trading 31.8% below its estimated fair value. The current Days Payable is 31.36, which is 18% below median its 10-year median of 38.20 and 60.7% below the Medical Distribution industry median of 79.81. Arjo AB's overall GF Score™ is 73/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Arjo AB (FRA:A39), the current Days Payable is 31.36 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Arjo AB (FRA:A39) Overvalued in 2026?
Based on GuruFocus' analysis, Arjo AB stock appears to be undervalued.
The current stock price of €2.23 is trading 31.8% below its estimated GF Value™ of €3.27.
GuruFocus considers Arjo AB to be Significantly Undervalued.
Key valuation signals for FRA:A39:
Days Payable: 31.36 (18% below median its 10-year median of 38.20)
GF Value™: €3.27 vs. price of €2.23 (31.8% below fair value)
Industry Position: 60.7% below the Medical Distribution median (#103 of 115)
No single metric tells the full story. See the FRA:A39 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Arjo AB is a supplier of medical devices, services, and solutions in Sweden. It serves its services to private and public institutions with acute care and long-term care. The company's offering includes products and solutions for patient handling, hygiene, disinfection, medical beds, therapeutic surfaces, venous thromboembolism (VTE) prevention and diagnostics. The company includes segments: Global Sales, North America, Diagnostics.
73GF Score
Get the complete analysis for FRA:A39
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:A39 has been successfully added to your 
